Biorepository for INvestigation of Diseases of the Lung (BRINDL) - Phase II

肺部疾病研究生物样本库 (BRINDL) - II 期

基本信息

批准号：
10683088
负责人：
GLORIA S PRYHUBER
金额：
$ 137.59万
依托单位：
UNIVERSITY OF ROCHESTER
依托单位国家：
美国
项目类别：
财政年份：
2019
资助国家：
美国
起止时间：
2019-08-23 至 2024-07-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10683088
关键词：
3-Dimensional Adopted Adult Age Age Years Alveolar Anatomy Atlases Awareness Bioinformatics Biological Assay Biopsy Cataloging Cause of Death Cell Nucleus Cell Separation Cells Child Childhood Collaborations Communities Contracts Country Data Databases Dedications Deposition Development Diagnostic Digital Imaging and Communications in Medicine Disease Dissociation Elements Ensure Equipment and supply inventories Erythema Infectiosum Ethics Family Generations Goals High Resolution Computed Tomography Histopathology Human Image Imaging Techniques Informatics Information Systems Infrastructure International Investigation Ischemia Legal Lung Lung diseases Medical center Medicine Metadata Methods Molecular Molecular Profiling Morbidity - disease rate Morphologic artifacts Neonatal Nonprofit Organizations Online Systems Organ Organ Donor Organ Procurements Pathologist Phase Physicians Population Pregnancy Prevention Procedures Process Program Development Qualifying Rare Diseases Recording of previous events Recovery Research Research Institute Research Personnel Resources Respiratory Disease Retrieval Sampling Sorting Source Specific qualifier value Specimen Standardization Structure Structure of parenchyma of lung System Techniques Time Tissue imaging Tissues United Network for Organ Sharing Universities Work biobank cell type chronic respiratory disease developmental disease disability-adjusted life years effective therapy emerging adult human disease human tissue image archival system lung development microCT mortality multiple omics novel organ procurement transplantation network preservation programs pulmonary function reconstruction response success tissue processing ultra high resolution years of life lost

项目摘要

Lung disease originating in the period between the late canalicular stage to mature alveolarization and peak lung function, between limits of viability and early adulthood, remains a major cause of morbidity and mortality. Research to discover novel treatments for these disorders is limited by the rarity of access to normal and diseased human lung across this age span. Having, as the original Human Tissue Core (HTC) for the Molecular Atlas of Lung Development Program (LungMAP), created the BioRepository for INvestigation of Diseases of the Lung (BRINDL), the University of Rochester Medical Center (URMC) submits this application in response to RFA-HL-19-021 to continue to serve as the HTC for LungMAP Phase 2 (LungMAP II). BRINDL now contains over 200 human full lung sets, 50 normal by history and histopathology, spanning mid-late gestation to adult age, as well as an additional 70+ with specified disease. It will continue to be URMC-HTC responsibility to sufficiently identify and manage tissue sources to meet the overall Program goal to build an open-access, comprehensive, molecular atlas of the late- stage developing and maturing lung. As the HTC, URMC will collect, process, deposit, and distribute to the four LungMAP Research Centers (RCs), and ultimately the greater research community, human lung samples representing late gestation through early adulthood in forms that will support temporal and spatial characterization of molecular profiles of functionally or anatomically defined cell types in the developing lung. Per the RFA, the URMC-HTC will support the expansion of LungMAP to up to 25 years of age and to include neonatal and pediatric rare lung disease as well as normal lung development. Because of the concern and complexity in recovering high-quality pediatric lungs in a standardized manner and with as little ischemia-induced artifact as possible, and the need to meet all legal and ethical standards, we continue to choose to work primarily through elements of the United Network of Organ Sharing, the federally contracted Organ Procurement and Transplantation Network (OPTN), and two non-profit organizations to whom are referred non-transplantable donated organs suitable for research, The National Disease Research Interchange (NDRI) and the International Institute for the Advancement of Medicine (IIAM). NDRI and IIAM work well with the OPTN and with families who approach them directly during a pregnancy or illness expected to be lethal. In addition, we have contacts with Pediatric Pulmonary Centers around the country to identify potential sources for rare lung disease samples. Our goal is to provide an additional 250 lung set donations, or at minimum biopsies, for inclusion in the LungMAP BRINDL biorepository. Our URMC-HTC, in collaboration with Seattle Children’s Research Institute, will prepare the donated organs and tissues to meet the needs of the LungMAP Phase II RCs.

肺部疾病起源于晚期阶段与成熟牙槽化的期间和峰值肺功能在生存能力和成年早期之间仍然是发病率的主要原因和死亡率。研究这些疾病的新疗法的研究受到罕见的限制在这个年龄范围内正常和厌恶的人类肺。具有原始人体组织核心（HTC）用于肺部发展计划（Lungmap）的分子地图集罗切斯特大学医学中心（URMC）的肺部疾病（Brindl）调查根据RFA-HL-19-021提交此申请，继续用作肺部的HTC 第2阶段（肺部II）。 Brindl现在包含200多个人类全肺套装，历史均为50种正常组织病理学，跨膜妊娠到成人年龄，以及另外的70+ 疾病。充分识别和管理组织源将继续是URMC-HTC的责任为了满足总体计划的目标，以建立一个晚期的开放式，全面的分子图集舞台发育和成熟肺。作为HTC，URMC将收集，处理，存放和分发到四个Lungmap研究中心（RCS），最终是更大的研究社区，人类肺在成年初期妊娠的样本以支持临时和空间的形式在发育中的功能或解剖学上定义的细胞类型的分子特征表征肺。根据RFA，URMC-HTC将支持将肺部扩展到25岁以下包括新生儿和小儿稀有肺部疾病以及正常的肺发育。因为以标准化的方式恢复高质量的小儿肺的关注和复杂性尽可能几乎没有缺血引起的人工制品，并且需要满足所有法律和道德标准，我们继续选择主要通过联合器官共享网络的要素，联邦合同的器官采购和移植网络（OPTN）和两个非营利组织被称为不可移植的组织，适合研究的组织，国家疾病研究互换（NDRI）和国际医学发展研究所（iiam）。 NDRI和IIAM与Optn以及与他们直接接近他们的家人合作预计怀孕或疾病是致命的。此外，我们与小儿肺中心接触全国各地识别罕见肺部疾病样本的潜在来源。我们的目标是提供额外的250个肺部设置捐赠或最低活检，以纳入肺部Brindl 生物座席。我们的URMC-HTC与西雅图儿童研究所合作，将准备捐赠了器官和组织以满足肺图II期RC的需求。